/
•
•
Context is everything.
Detailed stories on technology startups, business and economic current affairs.
Detailed stories on technology startups, business and economic current affairs.
Specialty drugs are fast becoming a lucrative market globally. And India’s largest drugmaker has done well to make the most of this opportunity so far. But it’s too soon to rest easy.
Specialty drugs are fast becoming a lucrative market globally. And India’s largest drugmaker has done well to make the most of this opportunity so far. But it’s too soon to rest easy.
The drugmaker’s reluctance to part with cash may have given it one of the strongest balance sheets in Indian pharma, but investors are increasingly rewarding risk takers.
Mounjaro’s blockbuster debut has already sparked a seismic shift across Indian healthcare, diagnostics and pharma. A marked change in consumer behaviour looks imminent.
The stock market has taken note of the company’s ambitious plans in the domestic market. But the path ahead is far from easy.
The drugmaker’s reluctance to part with cash may have given it one of the strongest balance sheets in Indian pharma, but investors are increasingly rewarding risk takers.
Mounjaro’s blockbuster debut has already sparked a seismic shift across Indian healthcare, diagnostics and pharma. A marked change in consumer behaviour looks imminent.
The stock market has taken note of the company’s ambitious plans in the domestic market. But the path ahead is far from easy.
